ClinicalTrials.Veeva

Menu

ORIC-I: Optimizing Recovery From Intensive Care: Mechanical Ventilation and Delirium

University of Pittsburgh logo

University of Pittsburgh

Status and phase

Terminated
Phase 3

Conditions

Delirium

Treatments

Other: Saline placebo
Drug: haloperidol

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT00300391
0505051
1K23HL078760-01A1 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to determine if treating delirious intensive care unit patients with haloperidol improves mortality.

Full description

Intensive care unit delirium is a serious medical condition that is associated with increased morbidity and mortality. In this study, 304 delirious mechanically ventilated subjects will be randomized to haloperidol 5mg IV every 12 hours or placebo to determine if treatment with haloperidol improves short and long-term mortality.

Enrollment

40 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All adult (>=18 years of age) mechanically ventilated patients admitted to the medical, surgical, trauma, or cardiothoracic ICUs of the UPMC main campus who are expected by the ICU clinical team to require >24 hours of mechanical ventilation

Exclusion criteria

  • Baseline QTc >480 milliseconds (ms); history of Parkinson's disease; pregnancy; history of schizophrenia or neurologic disease that would confound the delirium assessment; deafness or inability to understand English or Spanish; extubation prior to enrollment; previously enrolled in this study; patient, family, or attending physician refusal; death before enrollment; treatment with haloperidol within 2 days prior to ICU admission; and prisoners.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

40 participants in 2 patient groups, including a placebo group

haloperidol
Experimental group
Description:
Once diagnosed as delirious, randomized to haloperidol 5 mg IV
Treatment:
Drug: haloperidol
placebo
Placebo Comparator group
Description:
once diagnosed as delirious, received 5 mg saline placebo
Treatment:
Other: Saline placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems